Buy Crypto
Markets
Spot
FuturesBTC
Earn
Event Center
Rewards Hub
More
100%+ PoR
COLL

Collegium Pharmaceutical, Inc. (COLL)

NASDAQ
$25.94
+$0.40
(+1.57%)
Previous Close: ⁦$25.55⁩
Market Closed

Last updated: ⁦2026-11-19 07:59:40⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

Collegium Pharmaceutical, Inc. (COLL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $25.94, with a market capitalization of $793.98M and a P/E ratio of 20.80. Over the past 52 weeks, its price has ranged from $21.43 to $50.79. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

$793.98M

$25.36

$26.25

$24.57

$25.55

394.77K

762.23K

20.80

$50.79

$21.43

--

2026-09-30

Collegium Pharmaceutical, Inc. (COLL) Latest Closing Stock Price

Collegium Pharmaceutical, Inc. (COLL) last closed at $25.94 as of 2026-11-19 00:31:00, up 1.57% ($0.40) from the previous close of $25.55.

During the latest regular trading session, COLL traded between $24.57 and $26.25, with a volume of 394.77K shares. The closing price was near the upper end and near the lower end of its 52-week range.

Collegium Pharmaceutical, Inc. (COLL) 7-Day Stock Price Change

Over the past seven days, Collegium Pharmaceutical, Inc. (COLL) moved from $24.47 to $25.94, representing a gain of 6.02% ($1.47).

The stock traded between $23.99 and $26.25 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.

The average daily volume was 511.76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

COLL 52-Week Price Position

Position in Range: 15.4%

52W Low$21.43
52W High$50.79

COLL is currently trading at $25.94, placing it 15.4% of the way from its 52-week low of $21.43 to its 52-week high of $50.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Collegium Pharmaceutical, Inc. (COLL)?

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Collegium Pharmaceutical, Inc. Information

Industry
PHARMACEUTICAL PREPARATIONS
Employees
423
Exchange
NASDAQ
Company Website

COLL News

Latest news related to Collegium Pharmaceutical, Inc. and COLL stock.

  • Benzinga

    Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $41

    Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $48 to $41.

    Read Full Article
  • Massive

    LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

    Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.

    Read Full Article
  • Massive

    MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

    Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.

    Read Full Article

Ways to Trade COLL at MEXC

COLL MEXC RealStocks

Own real COLL shares through MEXC's regulated brokerage partner.


Suitable for long-term holding.

  • Own the actual shares
  • Receive dividends and voting rights
  • Buy fractional shares starting at $1

How to Buy Collegium Pharmaceutical, Inc. (COLL) Stock on MEXC

Eligible investors can buy real shares of Collegium Pharmaceutical, Inc. (COLL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for COLL and Place Your Order
Step 3: Search for COLL and Place Your Order
Open the RealStocks trading page and search for COLL. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Collegium Pharmaceutical, Inc. (COLL) stock price today?
Collegium Pharmaceutical, Inc. (COLL) is currently trading at $25.94, up 1.57% ($0.40) from the previous close of $25.55. Intraday prices update in real time during regular trading hours.
2.Is COLL stock going up or down today?
As of 2026-11-19 00:31:00, COLL is trading at $25.94, up 1.57% ($0.40) from its previous close of $25.55. The stock has traded between $24.57 and $26.25 during today’s regular session. Past price movements do not guarantee future results.
3.What is COLL pre-market price?
As of 2026-11-19 00:31:00, COLL is trading at $25.42 in pre-market trading, down 0.53% ($0.14) from the previous close of $25.55. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is COLL after-hours price?
As of 2026-11-19 00:31:00, COLL is trading at $25.94 in after-hours trading, down 0.01% ($0.00) from the regular-session close of $25.94. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is COLL stock trading now?
COLL trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does COLL sit relative to its 52-week high and low?
Over the past 52 weeks, COLL has traded between a low of $21.43 and a high of $50.79. At $25.94, the stock is positioned 15.4% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Collegium Pharmaceutical, Inc. in?
Collegium Pharmaceutical, Inc. (COLL) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Collegium Pharmaceutical, Inc.'s market capitalization and where is it listed?
Collegium Pharmaceutical, Inc. is listed on the NASDAQ exchange with a market capitalization of $793.98M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is COLL valued in terms of P/E ratio and EPS?
COLL trades at a P/E ratio of 20.80, based on trailing-twelve-month EPS of $1.23. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Collegium Pharmaceutical, Inc. pay a dividend?
Collegium Pharmaceutical, Inc. pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

Compliance Disclosure and Data Source

Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to COLL, including Stocks, Tokenized Stocks, and Stock Futures.

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

Search Stocks

COLL Stock Calculator

Estimate the value between COLL shares and USD.

COLL Shares to USD

COLL Shares
COLL
COLL
USD
USD
USD

1.00 COLL shares = 25.942 USD

Calculations are estimates based on the latest available price and are for reference only.